Diana Ernst, RPh

Editorial Director https://www.medicalbag.com

Diana Ernst, RPh, is the Editorial Director for MPR, part of the Haymarket Medical Network. Since 2003, Diana has worked to provide healthcare professionals with up-to-date drug information through MPR's print and digital offerings. She is a graduate of the Ernest Mario School of Pharmacy, Rutgers University.

All articles by Diana Ernst, RPh

Medicine

Novel Reversal Agent for Ticagrelor Gets FDA’s Breakthrough Therapy Designation

Diana Ernst, RPh

April 10, 2019

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to PB2452 (PhaseBio), an investigational reversal agent for ticagrelor.

Medicine

FDA Updates REMS for Transmucosal Immediate-Release Fentanyl Products

Diana Ernst, RPh

April 4, 2019

The Food and Drug Administration has announced that the Risk Evaluation and Mitigation Strategy (REMS) for transmucosal immediate-release fentanyl (TIRF) medications has been updated to better ensure the safe use of these products.

Medicine

FDA Approves New Valsartan Product Following Major Recall

Diana Ernst, RPh

March 20, 2019

The Food and Drug Administration (FDA) has approved a new generic version of Diovan (Novartis) that does not contain N-nitrosodimethylamine (NDMA) or N-nitrosodiethylamine (NDEA), 2 potentially carcinogenic impurities identified in several recalled valsartan products.

Medicine

Health Experts Review 41 Diets, Rank Best Overall for 2019

Diana Ernst, RPh

February 12, 2019

The popular Keto diet, which focuses on strict carbohydrate limitations and high-fat intake, was ranked at #38.

Medicine

AGS: Beers Criteria for Potentially Inappropriate Med Use in Older Adults Updated

Diana Ernst, RPh

February 6, 2019

Over 1400 clinical trials and research studies were reviewed by a panel of 13 experts to develop the new guideline.

Medicine

New Treatment Option for Serious Fungal Infections Now Available

Diana Ernst, RPh

February 1, 2019

Tolsura, which contains the azole antifungal itraconazole, is formulated using the Company’s proprietary SUBA (SUper-BioAvailable) technology which improves the bioavailability of poorly soluble drugs.

Medicine

FDA Clears Elevo Kit Snoring Intervention Device

Diana Ernst, RPh

January 31, 2019

The procedure, known as Elevoplasty, was investigated in the S.I.L.E.N.C.E. study (Snoring Intervention via Elevoplasty in a Non-surgical Clinical Environment) which included 52 patients.

Medicine

CDC: Top 10 Drugs Involved in Drug Overdose Deaths

Diana Ernst, RPh

December 13, 2018

Using data from the 2011 to 2016 National Vital Statistics System-Mortality files, the authors conducted a literal text analysis of death certificates to identify drugs mentioned as contributing to the cause of overdose death.